- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01241396
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
17 juni 2016 uppdaterad av: Janssen Pharmaceutica N.V., Belgium
An Observational Study of the Treatment of Multiple Myeloma in Routine Clinical Practice
The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY).
The aim of this registry is to provide accurate, descriptive information on the way Multiple Myeloma is treated in routine clinical practice.
The registry will collect information related to the treatment received for Multiple Myeloma.
About 3000 patients will take part in the study in about 28 countries.
The registry will only collect information that is already in medical files regarding treatment.
Patients will not be required to actively do anything in addition to what would be done without participating in this registry, nor will there be any procedures or interventions that are not already part of the current treatment.
Studieöversikt
Detaljerad beskrivning
There is a lack of objective data relating to variation in treatment practices and resource utilisation for Multiple Myeloma (MMY) patients between countries.
This void continues to hamper attempts to create meaningful health economic models for MMY treatment and impedes understanding of the MMY clinical arena.
This non-interventional observational study is designed to address the problem by providing a definitive picture of routine treatment and resource utilisation practices for MMY patients at any stage of treatment, independent of drug(s) used and treatment line across the different countries taking part.
A non-interventional study design has been selected to facilitate data collection about routine clinical practice.
This study seeks to obtain an appropriate subset of the true population of patients with MMY throughout Europe Middle East and Africa.
Many concerns exist when attempting to develop an unbiased study sample, including biases regarding the selection of patients to be enrolled.
Therefore, a multi-staged site and patient selection model will be used to reduce biases associated with patient and site selection.
The study seeks to enroll at least 3,000 patients.
It will deliver a description of everyday treatment practice of MMY.
Additional retrospective medical reviews will also be performed to collect information regarding disease history.
The primary objective of the study is to document and describe current treatment regimens and disease progression of patients with MMY.
Secondary objectives of the study involve understanding the MMY patient population and its generalisability to all treated MMY patients.
Additional goals of the study are to document and compare: (a) utilisation of current treatment regimens for MMY; (b) quality of life and health economic parameters associated with MMY treatment regimens; (c) the safety profile of current treatment regimens for MMY and the impact on resource utilisation; (d) the effectiveness of current treatment regimens for MMY.
The study will collect prospective data on efficacy, outcomes, health economic and safety parameters for all patients whenever available.
The resulting database will allow future health economic, pharmaco-epidemiological, and outcomes research, and provide important data from the clinical arena.
At least 3000 patients will be recruited to this study.
As this is an observational study, the decision of patients to take part in this study will not have any impact on the care they are receiving.
All treatment decisions will be made at the discretion of the participating physicians.
Only data available from routine clinical practice will be collected.
There are two phases of data collection in this study: (a) at baseline, the patient's historical treatment and resource utilisation data, where possible stretching back to diagnosis, will be recorded via electronic data capture; (b) following the baseline visit, the patient will enter a prospective data collection phase where data will be collected at least every three months.
At each data collection point, all changes since the previous data collection point will be collected.
Prospective data collection will continue until the study is complete or the patient is withdrawn from the study.
Data will continue to be captured until three years after the last patient is recruited to the study.
Interim analyses will be conducted at least annually to update the current data.
To monitor the safety profile of MMY treatment related to a Johnson and Johnson product, any unwanted effects that occur during the MMY treatment will be recorded Observational Study - No investigational drug administered
Studietyp
Observationell
Inskrivning (Faktisk)
2396
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Alger, Algeriet
-
Constantine, Algeriet
-
Oran, Algeriet
-
Setif, Algeriet
-
Tizi-Ouzou, Algeriet
-
-
-
-
-
Holstebro N/A, Danmark
-
Odense, Danmark
-
-
-
-
-
Tallinn N/A, Estland
-
Tartu, Estland
-
-
-
-
-
Avignon Cedex 9, Frankrike
-
Blois Cedex, Frankrike
-
Bordeaux Cedex, Frankrike
-
Brest Cedex 2, Frankrike
-
Clermont Ferrand Cedex 2, Frankrike
-
Le Mans Cedex 9, Frankrike
-
Montpellier, Frankrike
-
Nantes N/A, Frankrike
-
Nîmes, Frankrike
-
Nîmes Cedex 9, Frankrike
-
Perpignan Cedex, Frankrike
-
Pontoise, Frankrike
-
Rennes, Frankrike
-
St Brieuc Cedex 1, Frankrike
-
Troyes Cedex, Frankrike
-
-
-
-
-
Athens, Grekland
-
Larissa, Grekland
-
Thessalonikis, Grekland
-
-
-
-
-
Haifa, Israel
-
Kfar Saba, Israel
-
Petah-Tikva, Israel
-
Ramat Gan, Israel
-
-
-
-
-
Adana, Kalkon
-
Ankara, Kalkon
-
Antalya, Kalkon
-
Bursa, Kalkon
-
Istanbul, Kalkon
-
Izmir, Kalkon
-
Kayseri, Kalkon
-
Samsun, Kalkon
-
-
-
-
-
Zagreb, Kroatien
-
-
-
-
-
Riga, Lettland
-
-
-
-
-
Klaipeda, Litauen
-
Vilnius, Litauen
-
-
-
-
-
Skopje, Makedonien, fd jugoslaviska republiken
-
-
-
-
-
Bialystok, Polen
-
Brzozow, Polen
-
Bytom, Polen
-
Chorzow, Polen
-
Gdansk, Polen
-
Gorzow Wielkopolski, Polen
-
Katowice, Polen
-
Legnica, Polen
-
Lublin, Polen
-
Opole, Polen
-
Poznan, Polen
-
Rzeszow, Polen
-
Slupsk, Polen
-
Warszawa, Polen
-
Warszawa Poland, Polen
-
Wroclaw, Polen
-
Zamosc, Polen
-
-
-
-
-
Ponta Delgada, Portugal
-
Porto, Portugal
-
-
-
-
-
Kolomna, Ryska Federationen
-
Krasnodar, Ryska Federationen
-
Krasnogorsk, Ryska Federationen
-
Moscow, Ryska Federationen
-
Podolsk, Ryska Federationen
-
Saint Petersburg, Ryska Federationen
-
Saint-Petersburg, Ryska Federationen
-
Samara, Ryska Federationen
-
Saransk, Ryska Federationen
-
Tula, Ryska Federationen
-
Ulyanovsk, Ryska Federationen
-
Volgograd, Ryska Federationen
-
Vologda, Ryska Federationen
-
-
-
-
-
Ljubljana, Slovenien
-
-
-
-
-
Alicante, Spanien
-
Barcelona, Spanien
-
Caceres, Spanien
-
Ciudad Real, Spanien
-
Cádiz, Spanien
-
Guadalajara, Spanien
-
Jaen, Spanien
-
Leon, Spanien
-
Madrid, Spanien
-
Marbella, Spanien
-
Murcia, Spanien
-
Palma De Mallorca, Spanien
-
Salamanca N/A, Spanien
-
San Sebastian, Spanien
-
Sevilla, Spanien
-
Talavera De La Reina, Toledo, Spanien
-
Tarragona, Spanien
-
Zaragoza, Spanien
-
-
-
-
-
Bloemfontein, Sydafrika
-
Cape Town, Sydafrika
-
Durban, Sydafrika
-
Johannesburg, Sydafrika
-
-
-
-
-
Amberg, Tyskland
-
Aschaffenburg, Tyskland
-
Augsburg, Tyskland
-
Bad Soden, Tyskland
-
Bamberg, Tyskland
-
Berlin, Tyskland
-
Bielefeld, Tyskland
-
Bonn, Tyskland
-
Borken, Tyskland
-
Bottrop, Tyskland
-
Bremerhaven, Tyskland
-
Coburg, Tyskland
-
Dresden, Tyskland
-
Goslar, Tyskland
-
Hamburg, Tyskland
-
Hamm, Tyskland
-
Hannover, Tyskland
-
Hildesheim, Tyskland
-
Hof, Tyskland
-
Kaiserslautern, Tyskland
-
Lübeck, Tyskland
-
Mainz, Tyskland
-
Mayen, Tyskland
-
Mutlangen, Tyskland
-
München, Tyskland
-
Naunhof, Tyskland
-
Neunkirchen, Tyskland
-
Nürnberg, Tyskland
-
Olpe, Tyskland
-
Ostfildern, Tyskland
-
Rostock, Tyskland
-
Rotenburg, Tyskland
-
Saarbrÿcken, Tyskland
-
Stuttgart, Tyskland
-
Weiden, Tyskland
-
Würzburg, Tyskland
-
-
-
-
-
Cherkassy, Ukraina
-
Dnepropetrovsk, Ukraina
-
Donetsk, Ukraina
-
Ivano-Frankivsk, Ukraina
-
Kharkiv, Ukraina
-
Kherson, Ukraina
-
Khmelnitskiy, Ukraina
-
Kiev, Ukraina
-
Lutsk, Ukraina
-
Lviv, Ukraina
-
Nikolaev, Ukraina
-
Odessa, Ukraina
-
Poltava, Ukraina
-
Simferopol, Ukraina
-
Ternopil, Ukraina
-
Uzhgorod, Ukraina
-
Vinnitsa, Ukraina
-
Zaporizhzhya, Ukraina
-
Zhytomyr, Ukraina
-
-
-
-
-
Budapest, Ungern
-
Debrecen, Ungern
-
Pécs N/A, Ungern
-
Szeged, Ungern
-
Szombathely, Ungern
-
-
-
-
-
Graz, Österrike
-
Innsbruck, Österrike
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 99 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Sannolikhetsprov
Studera befolkning
The study will focus on enrolling consecutively, patients who are initiating any new line of therapy for Multiple Myeloma, regardless of the line of treatment.
Because this is a non-interventional study, intended to provide a picture of routine clinical practice, no guidance will be given on any aspect of treatment, patient clinical management or treatment dose selection.
Beskrivning
Inclusion Criteria:
- Requires commencement of a new line of treatment for MMY at any stage, regardless of type of therapy selected.
Exclusion Criteria:
- Patients currently participating in another investigational study or clinical trial.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
001
Any MMY treatment Any line of treatment for MMY
|
Any line of treatment for MMY
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Description of current treatment regimens for MMY.
Tidsram: Every 3 months from baseline to 3 years after last patient recruited
|
Every 3 months from baseline to 3 years after last patient recruited
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Utilisation of current treatment regimens for MMY
Tidsram: Every 3 months from baseline to 3 years after last patient recruited
|
Every 3 months from baseline to 3 years after last patient recruited
|
|
Quality of life and health economic parameters associated with MMY treatment regimens
Tidsram: Every 3 months from baseline to 3 years after last patient recruited
|
Every 3 months from baseline to 3 years after last patient recruited
|
|
Safety profile of current treatment regimens for MMY
Tidsram: Every 3 months from baseline to 3 years after last patient recruited
|
Every 3 months from baseline to 3 years after last patient recruited
|
|
The effectiveness of current treatment regimens for MMY
Tidsram: Every 3 months from baseline to 3 years after last patient recruited
|
Every 3 months from baseline to 3 years after last patient recruited
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2010
Primärt slutförande (Faktisk)
1 november 2014
Avslutad studie (Faktisk)
1 november 2014
Studieregistreringsdatum
Först inskickad
12 november 2010
Först inskickad som uppfyllde QC-kriterierna
12 november 2010
Första postat (Uppskatta)
16 november 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
20 juni 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
17 juni 2016
Senast verifierad
1 juni 2016
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Hematologiska sjukdomar
- Hemorragiska störningar
- Hemostatiska störningar
- Paraproteinemier
- Blodproteinstörningar
- Multipelt myelom
- Neoplasmer, Plasmacell
Andra studie-ID-nummer
- CR017410
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .